Cold Spring Harbor Laboratory: Discovery Could Improve MDS Cancer Treatment
September 25, 2019
September 25, 2019
COLD SPRING HARBOR, New York, Sept. 25 -- The Cold Spring Harbor Laboratory issued the following news:
Myelodysplastic syndrome (MDS), one of the most common blood cancers, has very few treatment options. Now, researchers at Cold Spring Harbor Laboratory (CSHL) have discovered a new and promising drug target for this deadly condition.
"At the moment, only a small portion of patients benefit from the standard therapy for MDS," said CSHL Fellow and cancer resear . . .
Myelodysplastic syndrome (MDS), one of the most common blood cancers, has very few treatment options. Now, researchers at Cold Spring Harbor Laboratory (CSHL) have discovered a new and promising drug target for this deadly condition.
"At the moment, only a small portion of patients benefit from the standard therapy for MDS," said CSHL Fellow and cancer resear . . .